Код жизни. Как защитить себя от развития злокачественных новообразований и сохранить тело здоровым до глубокой старости [заметки]

1

https://www.cdc.gov/obesity/data/prevalence-maps.html.

2

Центры по контролю и профилактике заболеваний США. – Здесь и далее прим. науч. ред.

3

Max Frankel, “Protracted War on Cancer,” New York Times, June 12, 1981, https://www.nytimes.com/1981/06/12/opinion/protracted-war-on-cancer.html.

4

J. C. Bailar III and E. M. Smith, “Progress Against Cancer?” New England Journal of Medicine 314, no. 19 (May 8, 1986): 1226–32.

5

Barron H. Lerner, “John Bailar’s Righteous Attack on the ‘War on Cancer,’ ” Slate, January 12, 2017, https://slate.com/technology/2017/01/john-bailar-reminded-us-of-the-value-of-evidence.html.

6

Clifton Leaf, The Truth in Small Doses (New York: Simon & Schuster, 2013), p. 25.

7

J. C. Bailar III and H. L. Gornik, “Cancer Undefeated,” New England Journal of Medicine 336, no. 22 (May 29, 1997): 1569–74.

8

https://www.nytimes.com/2009/04/24/health/policy/24cancer.html.

9

https://www.newyorker.com/tech/annals-of-technology/world-warcancer.

10

https://www.nytimes.com/2009/08/06/opinion/06watson.html.

11

https://slate.com/human-interest/2013/02/where-do-the-millions-of-cancer-research-dollars-go-every-year.html.

12

Siddhartha Mukherjee, The Emperor of all Maladies (New York: Simon & Schuster, 2010), p. 6.

13

https://www.cbc.ca/news/health/anesthesia-death-rates-improve-over-50-years-1.1200837.

14

E. H. Grubbe, “Priority in the Therapeutic Use of X-rays,” Radiology 21 (1933): 156–62.

15

M. A. Cleaves, “Radium: With a Preliminary Note on Radium Rays in the Treatment of Cancer,” Medical Record 64 (1903): 601–6.

16

E. B. Krumbhaar, “Role of the Blood and the Bone Marrow in Certain Forms of Gas Poisoning: I. Peripheral Blood Changes and Their Significance,” JAMA, 72 (1919): 39–41.

17

I. Berenblum et al., “The Modifying Influence of Dichloroethyl Sulphide on the Induction of Tumours in Mice by Tar,” Journal of Pathology and Bacteriology 32 (1929): 424–34.

18

https://scienceblog.cancerresearchuk.org/2014/08/27/mustard-gas-from-the-great-war-to-frontline-chemotherapy/.

19

R. J. Papac, “Origins of Cancer Therapy,” Yale Journal of Biology and Medicine 74 (2001): 391–98.

20

S. Farber et al., “Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-aminopteroyl-glutamic acid (aminopterin),” New England Journal of Medicine 238 (1948): 787–93.

21

M. C. Li, R. Hertz, and D. M. Bergenstal, “Therapy of Choriocarcinoma and Related Trophoblastic Tumors with Folic Acid and Purine Antagonists,” New England Journal of Medicine 259 (1958): 66–74.

22

E. J. Freireich, M. Karon, and E. Frei III, “Quadruple Combination Therapy (VAMP) for Acute Lymphocytic Leukemia of Childhood,” Proceedings of the American Association for Cancer Research 5 (1964): 20.

23

V. T. DeVita, A. A. Serpick, and P. P. Carbone, “Combination Chemotherapy in the Treatment of Advanced Hodgkin’s Disease,” Annals of Internal Medicine 73 (1970): 881–95.

24

Письмо Чарльза Дарвина Джозефу Долтону Гукеру, 1 августа 1857 г., DCPLETT-2130, Darwin Correspondence Project, https://www.darwinproject.ac.uk/letter/?docId=letters/DCP-LETT-2130.xml;query=DCP-LETT-2130;brand=default.

25

D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell 100, no. 1 (January 2000): 57–70.

26

D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell 144, no. 5 (March 4, 2011): 646–74, doi: 10.1016/j.cell.2011.02.013.

27

A. G. Renehan et al., “What Is Apoptosis, and Why Is It important?” BMJ 322 (2001): 1536–38.

28

J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: A Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics,” British Journal of Cancer 26, no. 4 (August 1972): 239–57.

29

J. W. Shay et al., “Hayflick, His Limit, and Cellular Ageing,” Nature Reviews Molecular Cell Biology 1, no. 1 (October 2000): 72–76, doi: 10.1038/35036093.

30

G. Watts, “Leonard Hayflick and the Limits of Ageing,” The Lancet 377, no. 9783 (June 18, 2011): 2075, doi: 10.1016/S0140–6736(11)60908–2.

31

https://www.theguardian.com/world/2010/apr/04/henrietta-lacks-cancer-cells.

32

O. Warburg, F. Wind, and E. J. Negelein, “The Metabolism of Tumors in the Body,” General Physiology 8, no. 6 (March 7, 1927): 519–30.

33

Так говорила Алиса в книге Льюиса Кэрролла «Приключения Алисы в стране чудес»

34

https://www.mayoclinic.org/diseases-conditions/cancer/symptoms-causes/syc-20370588.

35

D. E. Redmond, “Tobacco and Cancer: The First Clinical Report, 1761,” New England Journal of Medicine 282, no. 1 (January 1, 1970): 18–23.

36

J. R. Brown and J. L. Thornton, Percivall Pott (1714–1788) and Chimney Sweepers’ Cancer of the Scrotum,” British Journal of Industrial Medicine 14,no. 1 (January1957): 68–70.

37

https://www.asbestos.com/asbestos/history/.

38

K. M. Lynch and W. A. Smith, “Pulmonary Asbestosis III: Carcinoma of the Lung in Asbesto-silicosis,” American Journal of Cancer 24 (1935): 56–64.

39

B. I. Casteman, “Asbestos and Cancer: History and Public Policy,” British Journal of Industrial Medicine 48 (1991): 427–32.

40

J. C. McDonald and A. D. McDonald, “Epidemiology of Mesothelioma, ” in D. Lidel and K. Miller, eds., Mineral Fibers and Health (Boca Raton, FL: CRC Press, 1991).

41

M. Albin et al., “Asbestos and Cancer: An Overview of Current Trends in Europe,” Environmental Health Perspectives 107, Suppl. 2 (1999): 289–98, http.//ehpnetl.niehs.nih.gov/docs/1999/Suppl-2/289-298albin/abstract.html.

42

J. LaDou, “The Asbestos Cancer Epidemic,” Journal of Environmental Health Perspectives 112, no. 3 (2004): 285–90.

43

https://monographs.iarc.fr/agents-classified-by-the-iarc/.

44

Сейчас этот минерал называют настураном или уранинитом, здесь автор использует термин того времени, pitchblende (урановая смолка). – Прим. пер.

45

D. J. Shah et al., “Radiation-induced Cancer: A Modern View,” British Journal of Radiology 85, no. 1020 (2012): e1166–73.

46

K. Ozasa et al., “Studies of the Mortality of Atomic Bomb Survivors: Report 14, 1950–2003: An Overview of Cancer and Noncancer Diseases,” Radiation Research 177 (2012): 229–43.

47

B. R. Jordan, “The Hiroshima/Nagasaki Survivor Studies: Discrepancies Between Results and General Perception,” Genetics 203, no. 4 (2016): 1505–12.

48

J. F. Kerr et al., “Apoptosis: A Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics,” British Journal of Cancer 26 (1972): 239–57.

49

Выражение «going viral» трудно перевести на русский – оно сейчас значит в том числе «распространяется как мем». – Прим. пер.

50

Источник: I. Magrath, “Denis Burkitt and the African Lymphoma,” Ecancermedicalscience 3, no. 159 (2009): doi: 10.3332/ecancer.2009.159.

51

I. Magrath, “Denis Burkitt and the African lymphoma,” Ecancermedicalscience 3 (2009): 159, doi: 10.3332/ecancer.2009.159.

52

M. A. Epstein, B. G. Achong, and Y. M. Barr, “Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma,” The Lancet 1 (1964): 702–3, doi:10.1016/S0140-6736(64)91524–7.

53

J. S. Pagano et al., “Infectious Agents and Cancer: Criteria for a Causal Relation,” Seminars in Cancer Biology 14 (2004): 453–71.

54

Основные симптомы: лихорадка, боль в горле, увеличение подчелюстных лимфоузлов, обнаружение в крови атипичных мононуклеаров

55

D. P. Burkitt, “Etiology of Burkitt’s Lymphoma: An Alternative Hypothesis to a Vectored Virus,” Journal of the National Cancer Institute 42 (1969): 19–28.

56

Magrath, “Dennis Burkitt and the African Lymphoma.”

57

M. L. K. Chua et al., “Nasopharyngeal Carcinoma,” The Lancet 387, no. 10022 (2016): 1012–24.

58

F. Petersson, “Nasopharyngeal Carcinoma: A Review,” Seminars in Diagnostic Pathology 32, no. 1 (2015): 54–73.

59

E. Chang and H.-O. Adami. 2006. “The Enigmatic Epidemiology of Nasopharyngeal Carcinoma,” Cancer Epidemiol, Biomarkers and Prevention 15 (2006): 1765–77.

60

Nicholas Wade, “Special Virus Cancer Program: Travails of a Biological Moon Shot,” Science 174 (December 24, 1971): 1306–11.

61

https://www.nytimes.com/1974/06/19/archives/nationa l-cancer-institute-reorganizing-10yearold-viral-research.html.

62

T. M. Block et al., “A Historical Perspective on the Discovery and Elucidation of the Hepatitis B Virus,” Antiviral Research 131 (July 2016): 109–23, doi: 10.1016/j.antiviral.2016.04.012.

63

R. P. Beasley et al., “Hepatocellular Carcinoma and Hepatitis B Virus: A Prospective Study of 22 707 Men in Taiwan,” The Lancet 8256 (1981): 1129–33.

64

V. Vedham et al., “Early-Life Exposures to Infectious Agents and Later Cancer Development,” Cancer Medicine 4, no. 12 (2015): 1908–22.

65

H. J. Alter et al., “Posttransfusion Hepatitis After Exclusion of Commercial and Hepatitis-B Antigen-Positive Donors,” Annals of Internal Medicine 77, no. 5 (1972): 691–99.

66

http://www.vch.ca/Documents/public-health-nobel-winning-hpv.pdf.

67

J. M. Walboomers et al., “Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide,” Journal of Pathology 189, no. 1 (September 1999): 12–19.

68

L. Torre et al., “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians 65 (2012): 87–108.

69

M. Arbyn et al., “Prophylactic Vaccination Against Human Papillomaviruses to Prevent Cervical Cancer and Its Precursors,” Cochrane Database of Systematic Reviews 5, Article No. CD009069, 2018, doi: 10.1002/14651858.CD009069.pub3.

70

K. D. Crew and A. I. Neugut, “Epidemiology of Gastric Cancer,” World Journal of Gastroenterology 12, no. 3 (January 21, 2006): 354–62.

71

B. Linz et al., “An African Origin for the Intimate Association Between Humans and Helicobacter pylori,” Nature 445 (2007): 915–18.

72

http://discovermagazine.com/2010/mar/07-dr-drank-broth-gave-ulcer-solved-medical-mystery.

73

S. Suerbaum and P. Michetti P., “Helicobacter pylori Infection,” New England Journal of Medicine 347 (2002): 1175–86.

74

H. S. Youn et al., “Pathogenesis and Prevention of Stomach Cancer,” Journal of Korean Medical Science 11 (1996): 373–85.

75

A. M. Nomura, G. N. Stemmermann, and P. H. Chyou, “Gastric Cancer Among the Japanese in Hawaii,” Japanese Journal of Cancer Research 86 (1995): 916–23.

76

D. M. Parkin et al., “Global Cancer Statistics, 2002,” CA: A Cancer Journal for Clinicians 55 (2005): 74–108.

77

R. Mera et al., “Long-term Follow-up of Patients Treated for Helicobacter pylori Infection,” Gut 54 (2005): 1536–40.

78

M. E. Stolte et al., 2002. “Helicobacter and Gastric MALT Lymphoma,” Gut 50, Suppl. 3 (2002): III19–III24.

79

R. M. Peek Jr. and J. E. Crabtree, “Helicobacter Infection and Gastric Neoplasia,” Journal of Pathology 208 (2006): 233–48.

80

D. Parkin, “The Global Health Burden of Infection-associated Cancers in the Year 2002,” International Journal of Cancer 118 (2006): 3030–44.

81

J. Gayon, “From Mendel to Epigenetics: History of Genetics,” Comptes Rendus Biologies 339 (2016): 225–30.

82

T. Boveri, “Uber mehrpolige mitosen als mittel zur analyse des zellkerns,” Verh. D. Phys. Med. Ges. Wurzberg N. F. 35 (1902): 67–90.

83

A. Balmain, “Cancer Genetics: From Boveri and Mendel to Microarrays,” Nature Reviews 1 (2001): 77–82.

84

K. Bister, “Discovery of Oncogenes: The Advent of Molecular Cancer Research,” PNAS 112, no. 50 (2015): 15259–60.

85

L. Chin et al., “P53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis,” Cell 97 (1999): 527–38.

86

https://www.cancer.org/cancer/cancer-causes/general-info/known-and-probable-human-carcinogens.html.

87

A. Balmain and I. B. Pragnell, “Mouse Skin Carcinomas Induced in vivo by Chemical Carcinogens Have a Transforming Harvey-ras Oncogene,” Nature 303 (1983): 72–74.

88

https://www.cancer.gov/about-cancer/causes-prevention/risk/age.

89

P. Nowell and D. Hungerford, “A Minute Chromosome in Human Chronic Granulocytic Leukemia,” abstract, Science 132 (1960): 1497.

90

На российском рынке существуют препараты «Иматиниб» нескольких производителей, «Филахромин», «Гливек».

91

E. H. Romond et al., “Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2 Positive Breast Cancer,” New England Journal of Medicine 353 (2005): 1673–84.

92

Трое из которых биологические, а трое – приемные.

93

P. Lichtenstein, “Environmental and Heritable Factors in the Causation of Cancer,” New England Journal of Medicine 343 (2000): 78–85.

94

M. C. King, J. H. Marks, and J. B. Mandell, “Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2,” Science 302, no. 5645 (2003): 643–46.

95

L. A. Mucci et al., “Familial Risk and Heritability of Cancer Among Twins in Nordic Countries,” JAMA 315, no. 1 (January 5, 2006): 68–76.

96

A. R. David and M. R. Zimmerman, “Cancer: An Old Disease, a New Disease or Something in Between?” Nature Reviews Cancer 10 (2010): 728–33.

97

James W. Hampton, “Cancer Prevention and Control in American Indians/Alaska Natives,” American Indian Culture and Research Journal 16, no. 3 (1992): 41–49.

98

M. L. Sievers and J. R. Fisher, “Cancer in North American Indians: Environment versus Heredity,” American Journal of Public Health 73 (1983): 485–87; T. K. Young and J. W. Frank, “Cancer Surveillance in a Remote Indian Population in Northwestern Ontario,” American Journal of Public Health 73 (1983): 515–20.

99

I. M. Rabinowitch, “Clinical and Other Observations on Canadian Eskimos in the Western Arctic,” Canadian Medical Association Journal 34 (1936): 487.

100

O. Schafer et al., “The Changing Pattern of Neoplastic Disease in Canadian Eskimos,” Canadian Medical Association Journal 112 (1975): 1399–404.

101

F. S. Fellows, “Mortality in the Native Races of the Territory of Alaska, with Special Reference to Tuberculosis,” Public Health Reports (1896–1970) 49, no. 9 (March 2, 1934): 289–98.

102

J. T. Friborg and M. Melbye, “Cancer Patterns in Inuit Populations,” The Lancet Oncology 9, no. 9 (2008): 892–900.

103

R. G. Ziegler e al., “Migration Patterns and Breast Cancer Risk in AsianAmerican Women,” Journal of the National Cancer Institute 85, no. 22 (November 17, 1993): 1819–27.

104

J. Peto, “Cancer Epidemiology in the Last Century and the Next Decade,” Nature 411, no. 6835 (May 17, 2001): 390–95.

105

https://www.nytimes.com/2005/03/28/health/huge-genome-project-is-proposed-to-fight-cancer.html.

106

https://www.nytimes.com/2005/03/28/health/huge-genome-project-is-proposed-to-fight-cancer.html.

107

G. L. G. Miklos, “The Human Cancer Genome Project – One More Misstep in the War on Cancer,” Nature Biotechnology 23 (2005): 535–37.

108

https://www.cancer.gov/news-events/press-releases/2018/tcga-pancancer-atlas.

109

T. Sjöblom et al., “The Consensus Coding Sequences of Human Breast and Colorectal Cancers,” Science 314, no. 5797 (2006): 268–74.

110

https://www.scientificamerican.com/article/end-of-cancer-genome-project-prompts-rethink/.

111

L. D. Wood et al., “The Genomic Landscapes of Human Breast and Colorectal Cancers,” Science 318, no. 5853 (November 16, 2007): 1108–13.

112

S. Yachida et al., “Distant Metastasis Occurs Late During the Genetic Evolution of Pancreatic Cancer,” Nature 467, no. 7319 (October 28, 2010): 1114–17.

113

Bert Vogelstein et al., “Cancer Genome Landscapes,” Science 339, no. 6127 (March 29, 2013): 1546–58, doi: 10.1126/science.1235122.

114

B. Pereira et al., “The Somatic Mutation Profiles of 2,433 Breast Cancers Refines Their Genomic and Transcriptomic Landscapes,” Nature Communications 10, no. 7 (2016): 11479, doi: 10.1038/ncomms11479

115

C. Greenman et al., “Patterns of Somatic Mutation in Human Cancer Genomes,” Nature 446, no. 7132 (March 8, 2007): 153–8.

116

Vogelstein et al., “Cancer Genome Landscapes,” 1546–58.

117

Yachida et al., “Distant Metastasis Occurs Late During the Genetic Evolution of Pancreatic Cancer,” 1114–17.

118

L. A. Loeb et al., “A Mutator Phenotype in Cancer,” Cancer Research 61, no. 8 (April 15, 2001): 3230–39.

119

P. Lichtenstein, “Environmental and Heritable Factors in the Causation of Cancer,” New England Journal of Medicine 343 (2000): 78–85.

120

K. B. Jacobs et al., “Detectable Clonal Mosaicism and Its Relationship to Aging and Cancer,” Nature Genetics 44, no. 6 (May 6, 2012): 651–58.

121

https://www.nytimes.com/2018/10/18/science/cancer-genetic-mutations.html.

122

I. Martincorena et al., “Somatic Mutant Clones Colonize the Human Esophagus with Age,” Science 362, no. 6417 (October 18, 2018): 911–17, doi:10.1126/science.aau3879.

123

Популярная американская лотерея с розыгрышами джекпотов в виде ярких шоу и огромными суммами выигрышей.

124

A. G. Renehan et al., “The Prevalence and Characteristics of Colorectal Neoplasia in Acromegaly,” Journal of Clinical Endocrinology and Metabolism 85, no. 9 (September 2000): 3417–24.

125

C. A. Sheldon et al., “Incidental Carcinoma of the Prostate: A Review of the Literature and Critical Reappraisal of Classification,” Journal of Urology 124, no. 5 (November 1980): 626–31.

126

W. C. Hahn and R. A. Weinberg, “Mechanisms of Disease: Rules for Making Human Tumor Cells,” New England Journal of Medicine 347 (2002): 1593–1603.

127

T. Sjoblom et al., “The Consensus Coding Sequences of Human Breast and Colorectal Cancers,” Science 314 (2006): 268–74.

128

D. L. Stoler et al., “The Onset and Extent of Genomic Instability in Sporadic Colorectal Tumor Progression,” Proceedings of the National Academy of Sciences 96, no. 26 (1999): 15121–26.

129

H. Bower et al., “Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches

the Life Expectancy of the General Population,” Journal of Clinical Oncology 34, no. 24

(August 20, 2016): 2851–57, doi: 10.1200/JCO.2015.66.2866.

130

J. Elliott et al., “ALK Inhibitors for Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis,” PLoS One 19, no. 15 (February 19, 2020): e0229179, doi: 10.1371/journal.pone.0229179.

131

https://www.goodrx.com/crizotinib.

132

D. M. Hyman et al., “Implementing Genome-driven Oncology,” Cell 168, no. 4 (2017): 584–99.

133

I. F. Tannock and J. A. Hickman, “Limits to Personalized Cancer Medicine,” New England Journal of Medicine 375 (2016): 1289–94.

134

V. Prasad, “Perspective: The Precision Oncology Illusion,” Nature 537 (2016): S63.

135

F. Meric-Bernstam et al., “Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment onto Genomically Matched Clinical Trials,” Journal of Clinical Oncology 33, no. 25 (September 1, 2015): 2753–65.

136

https://ecog-acrin.org/nci-match-eay131/interim-analysis.

137

J. Marquart, E. Y. Chen, and V. Prasad, “Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome-driven Oncology,” JAMA Oncology 4, no. 8 (2018): 1093–1098.

138

D. S. Echt et al., “Mortality and Morbidity in Patients Receiving Encainide, Flecanide, or Placebo: The Cardiac Arrhythmia Suppression Trial,” New England Journal of Medicine 324 (1991): 781–88.

139

C. M. Booth and E. A. Eisenhauer, “Progression-free Survival: Meaningful or Simply Measurable?” Journal of Clinical Oncology 30 (2012): 1030–33.

140

V. Prasad et al., “A Systematic Review of Trial-Level Meta-Analyses Measuring the Strength of Association Between Surrogate End-Points and Overall Survival in Oncology,” European Journal of Cancer 106 (2019): 196–211, doi:10.1016/j.ejca.2018.11.012; Prasad et al., “The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses,” JAMA Internal Medicine 175, no. 8 (2015): 1389–98, doi: 10.1001/jamainternmed. 2015.2829.

141

R. Kemp and V. Prasad, “Surrogate Endpoints in Oncology: When Are They Acceptable for Regulatory and clinical decisions, and Are They Currently Overused?” BMC Medicine 15, no. 1 (2017): 134.

142

J. Puthumana et al., “Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation,” JAMA 320, no. 3 (2018): 301–3.

143

E. Y. Chen et al., “An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate,” JAMA Internal Medicine, doi:10.1001/jamainternmed.2019.0583.

144

B. Gyawali et al., “Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval,” JAMA Internal Medicine, doi:10.1001/jamainternmed.2019.0462.

145

K. Miller et al., “Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer,” New England Journal of Medicine 357 (2007): 2666–76.

146

R. B. D’Agostino Sr., “Changing End Points in Breast-Cancer Drug Approval: The Avastin Story,” New England Journal of Medicine 365, no. 2 (2011): e2.

147

https://www.medscape.com/viewarticle/767862.

148

M. Piccart et al., “Everolimus plus Exemestane for Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2,” Annals of Oncology 25, no. 12 (2014): 2357–62.

149

V. Prasad et al., “The Strength of Association Between Surrogate End Points and Survival in Oncology.”

150

V. Prasad and Sham Mailankody, “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval,” JAMA Internal Medicine 177, no. 11 (2017): 1569–75, doi:10.1001/jamainternmed.2017.3601.

151

E. Y. Chen et al., “Estimation of Study Time Reduction Using Surrogate End Points Rather than Overall Survival in Oncology Clinical Trials,” JAMA Internal Medicine TK, no. TK (year TK): doi:10.1001/jamainternmed.2018.8351.

152

T. Fojo et al., “Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality that Stifles Innovation and Creativity: The John Conley Lecture,” JAMA Otolaryngology Head and Neck Surgery 140, no. 12 (2014): 1225–36, doi:10.1001/jamaoto.2014.1570.

153

D. K. Tayapongsak et al., “Use of Word ‘Unprecedented’ in the Media Coverage of Cancer Drugs: Do ‘Unprecedented’ Drugs Live Up to the Hype?” Journal of Cancer Policy 14 (2017): 16–20.

154

M. V. Abola and V. Prasad, “The Use of Superlatives in Cancer Research,” JAMA Oncology 2, no. 1 (2016)): 139–41.

155

T. Rupp and D. Zuckerman, “Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints,” JAMA Internal Medicine 177, no. 2 (2017): 276–77, doi:10.1001/jamainternmed.2016.7761.

156

https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia—and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571–11e5-a4aa-f25866ba0dc6_story.html?noredirect=on&utm_term=.fe8da5c78c41.

157

Большая фармакология, или «биг фарма» – недоброжелательное обозначение группы крупнейших в мире производителей лекарств, часто сосредоточенных в первую очередь на получении прибыли.

158

Prasad and Mailankody, “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval,” 1569–75.

159

N. Gordon et al., “Trajectories of Injectable Cancer Drug Costs After Launch in the United States,” Journal of Clinical Oncology 36, no. 4 (February 1, 2018): 319–25, doi:10.1200/JCO.2016.72.2124.

160

V. Prasad, K. De Jesus, and S. Mailankody, “The High Price of Anticancer Drugs: Origins, Implications and Barriers, Solutions,” Nature Reviews Clinical Oncology 14, no. 6 (2017): 381–90.

161

https://www.igeahub.com/2018/05/28/10-best-selling-drugs-2018-oncology/.

162

https://www.genengnews.com/the-lists/the-top-15-best-sellingdrugs-of-2017/77901068.

163

S. Singhal et al., Antitumor Activity of Thalidomide in Refractory Multiple Myeloma,” New England Journal of Medicine 341, no. 21 (1999): 1565–71.

164

Geeta Anand, “How Drug’s Rebirth as Treatment for Cancer Fueled Price Rises,” Wall Street Journal, November 15, 2004, https://www.wsj.com/articles/SB110047032850873523.

165

Hagop Kantarjian et al., “High Cancer Drug Prices in the United States: Reasons and Proposed Solutions,” Journal of Oncology Practice 10, no. 4 (2014): e208–e211.

166

P. J. Neumann et al., “Updating Cost-effectiveness: The Curious Resilience of the $50,000-per-QALY Threshold,” New England Journal of Medicine 371, no. 9 (August 2014): 28796–97, doi: 10.1056/NEJMp1405158.

167

https://www.cdc.gov/dhdsp/programs/spha/economic_evaluation/docs/podcast_v.pdf.

168

D. A. Goldstein, “Cost-effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer,” Journal of Clinical Oncology 33, no. 32 (November 10, 2015): 3727–32, doi:10.1200/JCO.2015.61.9569.

169

S. Mailankody and V. Prasad, “Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs,” JAMA Oncology 1, no. 4 (2015): 539–40.

170

https://www.cnbc.com/2019/02/11/this-is-the-real-reason-most-americans-file-for-bankruptcy.html.

171

S. Paget, “The Distribution of Secondary Growths in Cancer of the Breast,” The Lancet 1 (1889): 99–101.

172

M. Esteller “Cancer Epigenomics: DNA Methylomes and Histone-Modification Maps,” Nature Reviews Genetics 8, no. 4 (April 2007): 286–98.

173

L. J. C. Rush et al., “Novel Methylation Targets in De Novo Acute Myeloid Leukemia with Prevalence of Chromosome 11 Loci,” Blood 97, no. 10 (2001): 3226–33, doi: 10.1182/blood.V97.10.3226.

174

A. D. Beggs et al., “Whole-genome Methylation Analysis of Benign and Malignant Colorectal Tumours,” Journal of Pathology 229, no. 5 (April 2013): 697–704, doi: 10.1002/path.4132.

175

I. Martincorena et al., “Somatic Mutant Clones Colonize the Human Esophagus with Age,” Science (October 18 2018): eaau3879, doi: 10.1126/science.aau3879.

176

https://www.aps.org/publications/apsnews/201003/nih.cfm.

177

Цитата из классического английского детского стихотворения.

178

R. A. Weinberg, “Coming Full Circle: From Endless Complexity to Simplicity and Back Again,” Cell 157, no. 1 (March 27, 2014): 267–71, doi: 10.1016/j.cell.2014.03.004.

179

https://www.theguardian.com/commentisfree/2011/apr/25/cancer-evolution-ancient-toolkit-genes.

180

https://www.newsweek.com/2017/07/28/cancer-evolution-cells-637632.html.

181

https://www.newsweek.com/2017/07/28/cancer-evolution-cells-637632.html.

182

Суперзлодей, враг Бэтмена.

183

Суперзлодей, враг Супермена.

184

Michael Marshall, “Timeline: The Evolution of Life,” New Scientist, July 14, 2009, https://www.newscientist.com/article/dn17453-timeline-the-evolution-of-life.

185

Эукариоты, не относящиеся к царствам животных, грибов и растений.

186

https://www.theguardian.com/world/2018/may/14/ione-christensen-canada-yukon-sourdough-starter-yeast.

187

A. H. Yona et al., “Chromosomal Duplication Is a Transient Evolutionary Solution to Stress,” Proceedings of the National Academy of Sciences USA 109, no. 51 (2012): 21010–15.

188

L. Cisneros et al., “Ancient Genes Establish Stress-induced Mutation as a Hallmark of Cancer,” PLoS One 12, no. 4 (2017): e0176258.

189

G. H. Heppner, “Tumor Heterogeneity,” Cancer Research 44 (1984): 2259–65.

190

Cancer Genome Atlas Research Network, “Integrated Genomic Analyses of Ovarian Carcinoma,” Nature 474 (2011): 609–15.

191

N. Navin et al., “Tumour Evolution Inferred by Single-cell Sequencing,” Nature 472 (2011): 90–94.

192

S. Nik-Zainal et al., “Mutational Processes Molding the Genomes of 21 Breast Cancers,” Cell 149 (2012): 979–93.

193

Charles Swanton, “Intratumor Heterogeneity: Evolution Through Space and Time,” Cancer Research 72, no. 19 (October 2012): 4875–82.

194

S. P. Shah et al., “Mutational Evolution in a Lobular Breast Tumour Profiled at Single Nucleotide Resolution,” Nature 461 (2009): 809–13.

195

M. Gerlinger et al., “Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing,” New England Journal of Medicine 366 (2012): 883–92.

196

L. Bai and W. G. Zhu, “p53: Structure, Function and Therapeutic Applications,” Journal of Molecular Cancer 2, no. 4 (2006): 141–53.

197

A. Kamb, S. Wee, and C. Lengauer, “Why Is Cancer Drug Discovery So Difficult?” Nature Reviews Drug Discovery 6 (2007): 115–20.

198

L. M. Byrd et al., “Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer,” Cancer Epidemiology, Biomarkers and Prevention 17, no. 6 (June 2008): 1535–42, doi: 10.1158/1055–9965.EPI-07–2792.

199

https://www.newsweek.com/2017/07/28/cancer-evolution-cells-637632.html.

200

https://www.mirror.co.uk/news/world-news/boy-born-tail-loses-monkey-5993397.

201

T. Domazet-Lošo and D. Tautz, “Phylostratigraphic Tracking of Cancer Genes Suggests a Link to the Emergence of Multicellularity in Metazoa,” BMC Biology 8, no. 66 (2010), https://doi.org/10.1186/1741–7007–8–66 PMID: 20492640.

202

A. A. Trigos et al., “Altered Interactions Between Unicellular and Multicellular Genes Drive Hallmarks of Transformation in a Diverse Range of Solid Tumors,” Proceedings of the National Academy of Sciences USA 114 (2017): 6406–11.

203

https://cosmic-blog.sanger.ac.uk/cosmic-release-v90/.

204

L. Cisneros et al., “Ancient Genes Establish Stress-induced Mutation as a Hallmark of Cancer,” PLoS One 12, no. 4 (2017): e0176258, https://doi.org/10.1371/journal.pone.0176258.

205

H. Chen et al., “The Reverse Evolution from Multi-cellularity to Unicellularity During Carcinogenesis,” Nature Communications 6 (2015): 6367.

206

Vogelstein et al., “Cancer Genome Landscapes,” Science 339 (2013): 1546–58.

207

Chen et al., “The Reverse Evolution from Multi-cellularity to Unicellularity During Carcinogenesis,” 6367.

208

H. Chen and X. He, “The Convergent Cancer Evolution Toward a Single Cellular Destination,” Molecular Biology and Evolution 33, no. 1 (2016): 4–12, doi:10.1093/molbev/msv212.

209

M. Vincent, “Cancer: A De-repression of a Default Survival Program Common to All Cells?” Bioessays 34 (2011): 72–82.

210

H. F. Dvorak, “Tumors: Wounds that Do Not Heal—Similarities Between Tumor Stroma Generation and Wound Healing,” New England Journal of Medicine 315, no. 26 (December 25, 1986): 1650–59.

211

L. Simonato et al., “Lung Cancer and Cigarette Smoking in Europe: An Update of Risk Estimates and an Assessment of Inter-country Heterogeneity,” International Journal of Cancer 91, no. 6 (March 15, 2001): 876–87.

212

S. Bhat et al., “Risk of Malignant Progression in Barrett’s Esophagus Patients: Results from a Large Population-Based Study,” Journal of the National Cancer Institute 103, no. 13 (July 6, 2001): 1049–57.

213

L. A. Anderson et al., “Risk Factors for Barrett’s Oesophagus and Oesophageal Adenocarcinoma: Results from the FINBAR Study,” World Journal of Gastroenterology 13, no. 10 (March 14, 2007): 1585–94.

214

N. D. Walter et al., “Wound Healing After Trauma May Predispose to Lung Cancer Metastasis,” American Journal of Respiratory Cell and Molecular Biology 44 (2011): 591–96.

215

R. P. DerHagopian et al., “Inflammatory Oncotaxis,” JAMA 240, no. 4 (1978): 374–75.

216

L. M. Burt et al., “Risk of Secondary Malignancies After Radiation Therapy for Breast Cancer: Comprehensive Results,” Breast 35 (October 2017): 122–29, doi: 10.1016/j.breast.2017.07.004.

217

M. Faurschou et al., “Malignancies in Wegener’s Granulomatosis: Incidence and Relation to Cyclophosphamide Therapy in a Cohort of 293 Patients,” Journal of Rheumatology 35, no. 1 (January 2008): 100–105.

218

J. A. Baltus et al., “The Occurrence of Malignancies in Patients with Rheumatoid Arthritis Treated with Cyclophosphamide: A Controlled Retrospective Follow-up,” Annals of the Rheumatic Diseases 42, no. 4 (August 1983): 368–73.

219

(лат.) образ жизни

220

H. Welch and W. C. Black, “Using Autopsy Series to Estimate the Disease ‘Reservoir’ for Ductal Carcinoma In Situ of the Breast: How Much More Breast Cancer Can We Find? Annals of Internal Medicine 127 (1997): 1023–28.

221

https://quoteinvestigator.com/2014/05/04/adapt/.

222

R. Doll and R. J. Peto, “The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today,” National Cancer Institute 66, no. 6 (June 1981): 1191–308.

223

W. J. Blot and R. E. Tarone, “Doll and Peto’s Quantitative Estimates of Cancer Risks: Holding Generally True for 35 Years,” Journal of the National Cancer Institute 107, no. 4 (2015): djv044.

224

D. P. Burkitt, “Some Diseases Characteristic of Modern Western Civilization,” British Medical Journal 1, no. 274 (1973): 274–78.

225

G. E. McKeown-Eyssen et al., “A Randomized Trial of a Low-Fat, High-Fiber Diet in the Recurrence of Colorectal Polyps,” Journal of Clinical Epidemiology 47 (1994): 525–36.

226

R. MacLennan et al., “Randomized Trial of Intake of Fat, Fiber, and Beta Carotene to Prevent Colorectal Adenomas: The Australian Polyp Prevention Project,” Journal of the National Cancer Institute 87 (1995): 1760–66.

227

C. S. Fuchs et al., “Dietary Fiber and the Risk of Colorectal Cancer and Adenoma in Women,” New England Journal of Medicine 340, no. 3 (January 21, 1999):169–76.

228

A. Schatzkin et al., “Lack of Effect of a Low-Fat, High-Fiber Diet on the Recurrence of Colorectal Adenomas,” New England Journal of Medicine 342 (2000): 1149–55.

229

B. V. Howard et al., “Low-fat Dietary Pattern and Risk of Cardiovascular Disease: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial,” JAMA 295, no. 6 (February 8, 2006): 655–66.

230

R. L. Prentice et al., “Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial,” JAMA 295, no. 6 (February 8, 2006): 629–42.

231

S. A. A. Beresford et al., “Low-Fat Dietary Pattern and Risk of Colorectal Cancer: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):643–654, doi:10.1001/jama.295.6.643.

232

Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, “The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers,” New England Journal of Medicine 330, no.13 (1994): 1029–35.

233

G. S. Omenn et al., “Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease,” New England Journal of Medicine 334, no. 18 (1996): 1150–55.

234

E. Lonn et al., “Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease,” New England Journal of Medicine 354 (2006): 1567–77.

235

B. F. Cole et al., “Folic Acid for the Prevention of Colorectal Adenomas: A Randomized Clinical Trial,” JAMA 297, no. 21 (June 6, 2007): 2351–59.

236

C. B. Ambrosone et al., “Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients with Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221), Journal of Clinical Oncology (December 19, 2019): JCO1901203, doi: 10.1200/JCO.19.01203.

237

K. H. Bønaa et al., “Homocysteine Lowering and Cardiovascular Events After Acute Myocardial Infarction,” New England Journal of Medicine 354, no. 15 (2006): 1578–88.

238

M. Ebbing et al., “Mortality and Cardiovascular Events in Patients Treated with Homocysteine-lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial,” JAMA 300, no. 7 (2008): 795–804.

239

M. Ebbing et al., “Cancer Incidence and Mortality After Treatment with Folic Acid and Vitamin B12,” JAMA 302, no. 19 (November 18, 2009): 2119–26, doi: 10.1001/jama.2009.1622.

240

S. Faber et al., “The Action of Pteroylglutamic Conjugates on Man,” Science 106 (1947): 619–21.

241

E. Cameron and L. Pauling, “Ascorbic Acid and the Glycosaminoglycans: An Orthomolecular Approach to Cancer and Other Diseases,” Oncology 27, no. 2 (1973): 181–92

242

B. Lee et al., “Efficacy of Vitamin C Supplements in Prevention of Cancer: A Meta-Analysis of Randomized Controlled Trials,” Korean Journal of Family Medicine 36, no. 6 (November 2015): 278–85.

243

S. Peller and C. S. Stephenson, “Skin Irritation and Cancer in the United States Navy,” American Journal of Medical Sciences 194 (1937): 326–33.

244

F. L. Apperly, “The Relation of Solar Radiation to Cancer Mortality in North American,” Cancer Research 1 (1941): 191–95.

245

C. F. Garland and F. C. Garland, “Do Sunlight and Vitamin D Reduce the Likelihood of Colon Cancer?” International Journal of Epidemiology 9 (1980): 227–31; W. B. Grant, “An Estimate of Premature Cancer Mortality in the US Due to Inadequate Doses of Solar Ultraviolet-B Radiation,” Cancer 94 (2002): 1867–75.

246

N. Keum and E. Giovannucci, “Vitamin D Supplements and Cancer Incidence and Mortality: A Meta-analysis,” British Journal of Cancer 111 (2014): 976–80.

247

K. K. Deeb, D. L. Trump, and C. S. Johnson, “Vitamin D Signalling Pathways in Cancer: Potential for Anticancer Therapeutics,” Nature Reviews Cancer 7 (2007): 684–700, doi: 10.1038/nrc2196.

248

D. Feldman et al., “The Role of Vitamin D in Reducing Cancer Risk and Progression,” Nature Reviews Cancer 14 (2014): 342–57.

249

J. E. Manson et al., “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease,” New England Journal of Medicine 380, no. 1 (January 3, 2019): 33–44, doi: 10.1056/NEJMoa1809944; J. E. Manson et al., “Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer,” New England Journal of Medicine 380, no. 1 (January 3, 2019): 23–32, doi: 10.1056/NEJMoa1811403.

250

R. Scragg et al., “Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial,” JAMA Oncology 4, 11 (November 2018): e182178, doi: 10.1001/jamaoncol.2018.2178.

251

J. Ju et al., “Cancer Preventive Activities of Tocopherols and Tocotrienols. Carcinogenesis 31, no. 4 (April 2010): 533–42; S. Mahabir et al., “Dietary Alpha-, Beta-, Gamma– and Delta-tocopherols in Lung Cancer Risk,” International Journal of Cancer 123 (2008): 1173–80.

252

I. M. Lee et al., “Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial,” JAMA 294 (2005): 56–65.

253

D. Albanes et al., “Alpha-Tocopherol and Beta-carotene Supplements and Lung Cancer Incidence in the Alpha-tocopherol, Beta-carotene Cancer Prevention Study: Effects of Base-line Characteristics and Study Compliance,” Journal of the National Cancer Institute 88 (1996): 1560–70.

254

J. M. Gaziano et al., “Vitamins E and C in the Prevention of Prostate and Total Cancer in Men: The Physicians’ Health Study II Randomized Controlled Trial,” JAMA 301 (2009): 52–62.

255

S. M. Lippman et al., “Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT),” JAMA 301 (2009): 39–51.

256

E. A. Klein et al., “Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT),” JAMA 306 (2011): 1549–56.

257

B. Lauby-Secretan et al., “Body Fatness and Cancer: Viewpoint of the IARC Working Group,” New England Journal of Medicine 375 (2016): 794–98.

258

E. E. Calle et al., “Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults,” New England Journal of Medicine 348, 17 (April 24, 2003): 1625–38.

259

https://www.cdc.gov/mmwr/volumes/66/wr/mm6639e1.htm.

260

Lauby-Secretan et al., “Body Fatness and Cancer,” 794–98.

261

N. Keum et al., “Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies,” Journal of the National Cancer Institute 107, no. 2 (March 10, 2015): ii: djv088, doi:10.1093/jnci/djv088.

262

F. Islami et al., “Proportion and Number of Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in the United States,” CA: A Cancer Journal for Clinicians 68, 1 (January 2018): 31–54, doi:10.3322/caac.21440.

263

H. Sung et al., “Emerging Cancer Trends Among Young Adults in the USA: Analysis of aPopulation-based Cancer Registry,” Lancet Public Health 4, no. 3 (March 1, 2019): https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30267-6/fulltext.

264

P. Rous, “The Influence of Diet of Transplanted and Spontaneous Mouse Tumors,” Journal of Experimental Medicine 20, no. 5 (1914): 433–51.

265

A. Tannenbaum, “The Dependence of Tumor Formation on the Composition of the Calorie-Restricted Diet as Well as on the Degree of Restriction,” Cancer Research 5, no. 11 (1945): 616–25.

266

A. H. Eliassen et al., “Adult Weight Change and Risk of Postmenopausal Breast Cancer,” JAMA 296, no. 2 (July 12, 2006): 193–201.

267

M. Rabinowitch, “Clinical and Other Observations on Canadian Eskimos in the Eastern Arctic,” Canadian Medical Association Journal 34 (1936): 487–501.

268

G. M. Brown, L. B. Cronk, and T. J. Boag, “The Occurrence of Cancer in an Eskimo,” Cancer 5, no. 1 (January 1952): 142–43.

269

G. J. Mouratoff et al., “Diabetes Mellitus in Eskimos,” JAMA 199, no. 13 (1967): 961–66, doi: 10.1001/jama.1967.03120130047006.

270

George J. Mouratoff et al., “Diabetes Mellitus in Eskimos After a Decade”, JAMA 226, no. 11 (1973): 1345–46.

271

Cynthia D. Schraer et al., “Prevalence of Diabetes Mellitus in Alaskan Eskimos, Indians, and Aleuts,” Diabetes Care 11 (1988): 693–700.

272

K. J. Acton et al., “Trends in Diabetes Prevalence Among American Indian and Alaska Native Children, Adolescents, and Young Adults,” American Journal of Public Health 92 (2002): 1485–90.

273

Etan Orgel, “The Links Between Insulin Resistance, Diabetes, and Cancer,” Current Diabetes Reports 13, no. 2 (April 2013): 213–22, doi:10.1007/s11892-012-0356–6.

274

P. T. Campbell et al., “Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults,” Diabetes Care 35 (2012): 1835–44.

275

S. R. Seshasai et al., “Diabetes Mellitus, Fasting Glucose, and Risk of CauseSpecific Death,” New England Journal of Medicine 364 (2011): 829–41.

276

Y. Chan et al., “Association Between Type 2 Diabetes and Risk of Cancer Mortality: A Pooled Analysis of Over 771,000 Individuals in the Asia Cohort Consortium,” Diabetologia 60, no. 6 (June 2017): 1022–32, doi: 10.1007/s00125-017-4229-z.

277

T. Stocks et al., “Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts,” PLoS Medicine 6 (2009): e1000201.

278

E. Giovannucci et al., “Diabetes and Cancer,” Diabetes Care 33 (2010): 1674–85; S. C. Larsson, N. Orsini, and A. Wolk, Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-analysis,” Journal of the National Cancer Institute 97 (2005): 1679–87; S. C. Larsson, C. S. Mantzoros, and A. Wolk, “Diabetes Mellitus and Risk of Breast Cancer: A Meta-analysis,” International Journal of Cancer 121 (2007): 856–62.

279

W. Wu et al., “Rising Trends in Pancreatic Cancer Incidence and Mortality in 2000–2014,” Clinical Epidemiology 10 (July 9, 2018): 789–97.

280

«Код ожирения», Джейсон Фанг, изд. «Бомбора», 2020 г.

281

B. E. Barker, H. Fanger, and P. Farnes, “Human Mammary Slices in Organ Culture: I. Methods of Culture and Preliminary Observations on the Effects of Insulin,” Experimental Cell Research 35 (1964): 437–48.

282

D. LeRoith et al., “The Role of Insulin and Insulin-like Growth Factors in the Increased Risk of Cancer in Diabetes,” Rambam Maimonides Medical Journal 2, no. 2 (2011): e0043.

283

E. J. Gallagher and D. LeRoith, “The Proliferating Role of Insulin and Insulin-like Growth Factors in Cancer,” Trends in Endocrinology and Metabolism 21, no. 10 (October 2010): 610–18.

284

V. Papa et al., “Elevated Insulin Receptor Content in Human Breast Cancer,” Journal of Clinical Investigations 86 (1990): 1503–10.

285

J. Ma et al., “A Prospective Study of Plasma C-peptide and Colorectal Cancer Risk in Men,” Journal of the National Cancer Institute 96 (2004): 546–53.

286

R. Kaaks et al., “Serum C-Peptide, Insulin-like Growth Factor (IGF) I, IGF-Binding Proteins, and Colorectal Cancer Risk in Women,” Journal of the National Cancer Institute 92, no. 19 (October 4, 2000): 1592–600.

287

E. K. Wei et al., “A Prospective Study of C-peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women,” Cancer Epidemiology, Biomarkers and Prevention 14 (2005): 850–55.

288

T. Tsujimoto et al., “Association Between Hyperinsulinemia and Increased Risk of Cancer Death in Nonobese and Obese People: A Population-based Observational Study,” International Journal of Cancer 141 (2017): 102–11.

289

M. J. Gunter et al., “Breast Cancer Risk in Metabolically Healthy but Overweight Postmenopausal Women,” Cancer Research 75, no. 2: 270–74.

290

https://www.bbc.com/news/health-26065673.

291

C. J. Currie et al., “Mortality and Other Important Diabetes-related Outcomes with Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes,” Journal of Clinical Endocrinology and Metabolism 98, no. 2 (February 2013): 668–77.

292

S. L. Bowker et al., “Increased Cancer-related Mortality for Patients with Type 2 Diabetes Who Use Sulfonylureas or Insulin,” Diabetes Care 29 (2006): 254–58.

293

C. J. Currie, C. D. Poole, and E. A. M. Gale, “The Influence of Glucoselowering Therapies on Cancer Risk in Type 2 Diabetes,” Diabetologia 52 (2009): 1766–77, doi 10.1007/s00125-009-1440–6.

294

Y. X. Yang, S. Hennessy, and J. D. Lewis, “Insulin Therapy and Colorectal Cancer Risk Among Type 2 Diabetes Mellitus Patients,” Gastroenterology 127 (2004): 1044–50.

295

K. B. Michaels and W. C. Willett, “Breast Cancer: Early Life Matters,” New England Journal of Medicine 351 (2004): 1679–81.

296

P. A. Van den Brandt, “Pooled Analysis of Prospective Cohort Studies on Height, Weight, and Breast Cancer Risk,” American Journal of Epidemiology 152, no. 6 (September 15, 2000): 514–27.

297

M. Ahlgren et al., “Growth Patterns and the Risk of Breast Cancer in Women,” New England Journal of Medicine 351 (2004): 1619–26.

298

J. Green et al., “Height and Cancer Incidence in the Million Women Study: Prospective Cohort, and Meta-analysis of Prospective Studies of Height and Total Cancer Risk,” Lancet Oncology 12, no. 8 (August 2011): 785–94, doi: 10.1016/S1470–2045(11)70154–1.

299

https://www.irishtimes.com/life-and-style/health-family/lifestyle-linked-to-huge-increase-in-short-sightedness-1.3397726.

300

Elie Dolgin, “The Myopia Boom,” Nature 519, no. 19 (2015): 276–78.

301

L. C. Cantley, “The Phosphoinositide 3-Kinase Pathway,” Science 296, no. 5573 (May 31, 2002): 1655–57.

302

Lewis C. Cantley, “Seeking Out the Sweet Spot in Cancer Therapeutics: An Interview with Lewis Cantley,” Disease Models and Mechanisms 9, no. 9 (September 1, 2016): 911–16, doi: 10.1242/dmm.026856.

303

H. Tan et al., “Genome-wide Mutational Spectra Analysis Reveals Significant Cancer-specific Heterogeneity,” Scientific Reports 5, no. 12566 (2015): doi: 10.1038/srep12566.

304

L. C. Cantley, “Cancer, Metabolism, Fructose, Artificial Sweeteners and Going Cold Turkey on Sugar,” BMC Biology 12, no. 8 (2014).

305

M. Barbieri et al., “Insulin/IGF-I-signaling Pathway: An Evolutionarily Conserved Mechanism of Longevity from Yeast to Humans,” American Journal of Physiology-Endocrinology and Metabolism 285 (2003): E1064–E1071.

306

D. A. Fruman et al., “The PI3K Pathway in Human Disease,” Cell 170, no. 4 (August 10, 2017): 605–35, doi: 10.1016/j.cell.2017.07.029.

307

Pal A. et al., “PTEN Mutations as a Cause of Constitutive Insulin Sensitivity and Obesity,” New England Journal of Medicine 367 (2012): 1002–11.

308

D. L. Riegert-Johnson et al., “Cancer and Lhermitte-Duclos Disease Are Common in Cowden Syndrome Patients,” Hereditary Cancer in Clinical Practice 8, no. 6 (2010): https://doi.org/10.1186/1897–4287–8–6.

309

D. P. Burkitt, “Some Diseases Characteristic of Modern Western Civilization,” BMJ 1, no. 5848 (February 3, 1973): 274–78, doi: 10.1136/bmj.1.5848.274.

310

http://discovermagazine.com/2013/april/19-double-edged-genes.

311

A. Janecka et al., “Clinical and Molecular Features of Laron Syndrome, a Genetic Disorder Protecting from Cancer,” In Vivo 30, no. 4 (July—August 2016): 375–81.

312

J. Guevara-Aguirre et al., “Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-aging Signaling, Cancer, and Diabetes in Humans,” Science Translational Medicine 3, no. 7 (February 16, 2011): 70ra13 doi: 10.1126/scitranslmed.3001845.

313

J. Jones and D. Clemmons, “Insulin-like Growth Factors and Their Binding Proteins: Biological Actions,” Endocrine Reviews 16 (1995): 3–34; R. C. Baxter, J. M. Bryson, and J. R. Turtle, “Somatogenic Receptors of Rat Liver: Regulation by Insulin,” Endocrinology 107, no. 4 (1980): 1176–81; S. J. Moschos and C. S. Mantzoros, “The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications,” Oncology 63 (2002): 317–32; E. Giovannucci and D. Michaud, “The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas,” Gastroenterology 132 (2007): 2208–25.

314

M. J. Gunter et al., “A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer,” Cancer Epidemiology, Biomarkers and Prevention 17, no. 4 (2008): 921–29.

315

M. J. Gunter et al., “Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women,” Cancer Research 68, no. 1 (2008): 329–37.

316

A. Canonici et al., “Insulin-like Growth Factor-I Receptor, E-cadherin and Alpha-V Integrin Form a Dynamic Complex Under the Control of Alpha-catenin,” International Journal of Cancer 122 (2008): 572–82.

317

R. Palmqvist et al., “Plasma Insulin-like Growth Factor 1, Insulin-like Growth Factor Binding Protein 3, and Risk of Colorectal Cancer: A Prospective Study in Northern Sweden,” Gut 50 (2002): 642–46.

318

J. Ma et al., “Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-like Growth Factor (IGF)-1 and IGF-binding Protein-3,” Journal of the National Cancer Institute 91 (1999): 620–25.

319

https://business.financialpost.com/news/did-a-canadian-medical-expedition-lead-to-the-discovery-of-an-anti-aging-pill.

320

Hara, K. et al., “Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 Through a Common Effector Mechanism,” Journal of Biological Chemistry 273 (1998): 14484–94.

321

B. Magnuson et al., “Regulation and Function of Ribosomal Protein S6 Kinase (S6K) Within mTOR Signaling Networks,” The Biochemical Journal 441, no. 1 (2012): 1–21.

322

https://www.nih.gov/news-events/nih-research-matters/organ-transplants-cancer-risk.

323

H. Populo et al., “The mTOR Signalling Pathway in Human Cancer,” International Journal of Molecular Science 13 (2012): 1886–918, doi:10.3390/ijms13021886.

324

S. A. Forbes et al., “COSMIC: Mining Complete Cancer Genomes in the Catalogue of Somatic Mutations in Cancer,” Nucleic Acids Research 39 (2011): D945–D950.

325

A. G. Renehan, C. Booth, and C. S. Potten, “What Is Apoptosis, and Why Is It Important? British Medical Journal 322 (2001): 1536–38.

326

Y. H. Tseng et al., “Differential Roles of Insulin Receptor Substrates in the Anti-apoptotic Function of Insulin-like Growth Factor-1 and Insulin,” Journal of Biological Chemistry 277 (2002): 31601–11.

327

H. Zong et al., “AMP Kinase Is Required for Mitochondrial Biogenesis in Skeletal Muscle in Response to Chronic Energy Deprivation,” Proceedings of the National Academy of Sciences USA 99 (2002): 15983–87.

328

H. J. Weir et al., “Dietary Restriction and AMPK Increase Life Span via Mitochondrial Network and Peroxisome Remodeling,” Cell Metabolism 26 (2017): 1–13.

329

A. M. Otto, “Warburg Effect(s): A Biographical Sketch of Otto Warburg and His Impacts on Tumor Metabolism,” Cancer and Metabolism 5, no. 5 (2016), doi 10.1186/s40170-016-0145–9.

330

O. Warburg et al., “Versuche an überlebendem carcinom-gewebe,” Wienerklinische Wochenschrift 2 (1923): 776–77.

331

O. Warburg, “On the Origin of Cancer,” Science 123, no. 3191 (1956): 309–14.

332

F. Weinberg et al., “Mitochondrial Metabolism and ROS Generation Are Essential for Kras-mediated Tumorigenicity,” Proceedings of the National Academy of Sciences USA 107 (2010): 8788–93; A. S. Tan et al., “Mitochondrial Genome Acquisition Restores Respiratory Function and Tumorigenic Potential of Cancer Cells Without Mitochondrial DNA,” Cell Metabolism 21 (2015): 81–94; V. R. Fantin, J. St-Pierre, and P. Leder, “Attenuation of LDH-A Expression Uncovers a Link Between Glycolysis, Mitochondrial Physiology, and Tumor Maintenance,” Cancer Cell 9 (2006): 425.

333

C-H. Chang et al., “Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis,” Cell 153, no. 6 (2013): 1239–51.

334

X. L. Zu and M. Guppy, “Cancer Metabolism: Facts, Fantasy, and Fiction,” Biochemical and Biophysical Research Communications 313 (2004): 459–65.

335

W. H. Koppenol et al., “Otto Warburg’s Contributions to Current Concepts of Cancer Metabolism,” Nature Reviews Cancer 11, no. 5 (May 2011): 325–37, doi: 10.1038/nrc3038.

336

M. G. Vander Heiden, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324, no. 5930 (May 22, 2009): 1029–33.

337

R. B. Robey and N. Hay, “Is AKT the ‘Warburg Kinase’?—AKT: Energy Metabolism Interactions and Oncogenesis,” Seminars in Cancer Biology 19 (2009): 25–31.

338

R. C. Osthus et al., “Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc,” Journal of Biological Chemistry 275 (2000): 21797–800.

339

S. Venneti et al., “Glutamine-based PET Imaging Facilitates Enhanced Metabolic Evaluation of Gliomas in Vivo,” Science Translational Medicine 7, no. 274 (February 11, 2015): 274ra17.

340

H. Eagle, “Nutrition Needs of Mammalian Cells in Tissue Culture,” Science 122 (1955): 501–14.

341

David R. Wise and Craig B. Thompson, “Glutamine Addiction: A New Therapeutic Target in Cancer,” Trends in Biochemical Sciences 35, no. 8 (August 2010): 427–33, doi:10.1016/j.tibs.2010.05.003.

342

A. Carracedo, “Cancer Metabolism: Fatty Acid Oxidation in the Limelight,” Nature Reviews Cancer 13, no. 4 (April 2013): 227–32.

343

Luana Schito and Gregg L. Semenza, “Hypoxia-inducible Factors: Master Regulators of Cancer Progression,” Trends in Cancer Research 2, no. 12 (2016): 758–70.

344

G. L. Semenza, “Hypoxia-Inducible Factor 1 and Cancer Pathogenesis,” IUBMB Life 60, no. 9 (2008): 591–97.

345

G. L. Semenza, “HIF-1 Mediates Metabolic Responses to Intratumoral Hypoxia and Oncogenic Mutations,” Journal of Clinical Investigations 123 (2013): 3664–71.

346

R. A. Gatenby, “The Potential Role of Transformation-induced Metabolic Changes in Tumor-Host Interaction,” Cancer Research 55 (1995): 4151–56.

347

V. Estrella et al., “Acidity Generated by the Tumor Microenvironment Drives Local Invasion,” Cancer Research 73, no. 5 (March 1, 2013): 1524–35, doi:10.1158/0008–5472.CAN-12–2796.

348

L. Schwartz et al., “Out of Warburg Effect: An Effective Cancer Treatment Targeting the Tumor Specific Metabolism and Dysregulated pH,” Seminars in Cancer Biology, http://dx.doi.org/doi:10.1016/j.semcancer.2017.01.005.

349

O. Trabold et al., “Lactate and Oxygen Constitute a Fundamental Regulatory Mechanism in Wound Healing,” Wound Repair and Regeneration 11 (2003): 504–9.

350

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastasis.

351

C. L. Chaffer and R. A. Weinberg, “A Perspective on Cancer Cell Metastasis,” Science 33, no. 6024 (2011): 1559–64.

352

T. I. Brandler, “Large Fibrolipoma,” British Medical Journal 1 (1894): 574.

353

V. Estrella, T. Chen, M. Lloyd et al., “Acidity Generated by the Tumor Microenvironment Drives Local Invasion,” Cancer Research 73 (2013): 1524–35.

354

A. F. Chambers, A. C. Groom, and I. C. MacDonald, “Dissemination and Growth of Cancer Cells in Metastatic Sites,” Nature Reviews Cancer 2 (2002): 563–72.

355

C. A. Klein, “Parallel Progression of Primary Tumours and Metastases,” Nature Reviews Cancer 9 (2009): 302–12, 10.1038/nrc2627.

356

H. R. Carlson, “Carcinoma of Unknown Primary: Searching for the Origin of Metastases,” JAAPA 22, no. 8 (2009): 18–21.

357

S. Meng et al., “Circulating Tumor Cells in Patients with Breast Cancer Dormancy,” Clinical Cancer Research 10 (2004): 8152–62.

358

S. Nagrath et al., “Isolation of Rare Circulating Tumor Cells in Cancer Patients by Microchip Technology,” Nature 450 (2007): 1235–39.

359

D. Tarin et al., “Mechanisms of Human Tumor Metastasis Studied in Patients with Peritoneovenous Shunts,” Cancer Research 44 (1984): 3584–92.

360

S. Braun et al., “A Pooled Analysis of Bone Marrow Micro-Metastasis in Breast Cancer,” New England Journal of Medicine 353 (2005): 793–802.

361

J. Massagué and A. C. Obenauf, “Metastatic Colonization,” Nature 529, no. 7586 (January 21, 2016): 298–306, doi: 10.1038/nature17038.

362

D. P. Tabassum and K. Polyak, “Tumorigenesis: It Takes a Village,” Nature Reviews Cancer 15 (2015): 473–83.

363

D. Hanahan and L. M. Coussens, “Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment,” Cancer Cell 21 (2012): 309–22.

364

Mi-Young Kim, “Tumor Self-Seeding by Circulating Cancer Cells,” Cell 139, no. 7 (December 24, 2009): 1315–26, doi: 10.1016/j.cell.2009.11.025.

365

Многократно увеличивает.

366

P. K. Brastianos, “Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets,” Cancer Discovery 5, no. 11 (November 2015): 1164–77.

367

L. Ding et al., “Genome Remodelling in a Basal-like Breast Cancer Metastasis and Xenograft,” Nature 464 (2010): 999–1005.

368

E. S. Ford et al., “Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000,” New England Journal of Medicine 356, no. 23 (2007): 2388–98

369

H. K. Weir et al., “Heart Disease and Cancer Deaths: Trends and Projections in the United States, 1969–2020,” Preventing Chronic Disease 13 (2016): 160211, doi: https://doi.org/10.5888/pcd13.160211.

370

K. G. Hastings et al., “Socioeconomic Differences in the Epidemiologic Transition from Heart Disease to Cancer as the Leading Cause of Death in the United States, 2003 to 2015,” Annals of Internal Medicine 169, no. 12 (December 18, 2018): 836–44.

371

https://www.cancer.org/latest-news/facts-and-figures-2019.html.

372

https://www.health.harvard.edu/blog/surgeon-generals-1964-report-making-smoking-history-201401106970.

373

https://www.cdc.gov/media/releases/2018/p0118-smoking-rates-declining.html.

374

F. Islami et al., “Proportion and Number of Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in the United States,” 31–54.

375

M. Inoue and S. Tsugane, “Epidemiology of Gastric Cancer in Japan,” Postgraduate Medical Journal 81 (2005): 419–24.

376

T. Tonda et al., “Detecting a Local Cohort Effect for Cancer Mortality Data Using a Varying Coefficient Model,” Journal of Epidemiology 25, no. 10 (2015): 639–46, doi: 10.2188/jea.JE20140218.

377

Y. Chen et al., “Excess Body Weight and the Risk of Primary Liver Cancer: An Updated Meta-analysis of Prospective Studies,” European Journal of Cancer 48, no. 14 (2012): 2137–45.

378

H. C. Taylor and H. B. Guyer, “A Seven-Year History of Early Cervical Cancer,” American Journal of Obstetrics and Gynecology 52 (1946): 451–55.

379

P. J. Shaw, “The History of Cervical Screening—I: The Pap Test,” Journal of Obstetrics and Gynaecology Canada 22, no. 2 (2000): 110–14.

380

G. N. Papanicolaou and H. F. Traut, “The Diagnostic Value of Vaginal Smears in Carcinoma of the Uterus,” American Journal of Obstetrics and Gynecology 42, no. 2 (1941): 193–206.

381

http://www.scielo.br/scielo.php?script=sci_arttext&pid= S0104–59702010000500004#nt11.

382

J. P. Lockhart-Mummery and C. Dukes, “The Precancerous Changes in the Rectum and Colon,” Surgery, Gynecology and Obstetrics 36 (1927): 591–96.

383

S. J. Winawer et al., “Prevention of Colorectal Cancer by Colonoscopic Polypectomy: The National Polyp Study Workgroup,” New England Journal of Medicine 329 (1993): 1977–81.

384

A. G. Zauber et al., “Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths,” New England Journal of Medicine 366 (2012): 687–96.

385

J. S. Mandel et al., “Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood: Minnesota Colon Cancer Control Study,” New England Journal of Medicine 328 (1993): 1365–71.

386

Хоумран – удар в бейсболе, после которого мяч вылетает за пределы поля. Он приносит команде бьющего много очков. – Прим. пер.

387

Centers for Disease Control and Prevention, “Vital Signs: Colorectal Cancer Screening Test Use—United States, 2012,” Morbidity and Mortality Weekly Report 62 (2012): 881–88.

388

P. C. Gøtzsche and K. J. Jørgensen. “Screening for Breast Cancer with Mammography,” Cochrane Database Systemic Reviews 6 (2013): CD001877.

389

N. Biller-Andorno and P. Juni, “Abolishing Mammography Screening Programs? A View from the Swiss Medical Board,” New England Journal of Medicine 370, no. 21 (May 22, 2014): 1965–67, doi: 10.1056/NEJMp1401875.

390

A. Bleyer and H. G. Welch, “Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence,” New England Journal of Medicine 367 (2012): 1998–2005.

391

Резекция (частичное удаление) молочной железы.

392

Magnus Løberg et al., “Benefits and Harms of Mammography Screening,” Breast Cancer Research 17 (2015): 63, doi: 10.1186/s13058-015-0525-z.

393

H. J. Burstein et al., “Ductal Carcinoma In Situ of the Breast. New England Journal of Medicine 350, no. 14 (2004): 1430–41, PMID: 15070793.

394

H. D. Nelson et al., “Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 124, AHRQ Publication No. 14–05201-EF-1, Agency for Healthcare Research and Quality, Rockville, MD, 2016.

395

Nelson et al., “Screening for Breast Cancer,” 16.

396

G. De Angelis et al., “Twenty Years of PSA: From Prostate Antigen to Tumor Marker,” Reviews in Urology 9, no. 3 (Summer 2007): 113–23.

397

W. J. Catalona et al., “Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves,” Journal of Urology 152, no. 6, part 1 (1994): 2037–42; I. M. Thompson et al., “Prevalence of Prostate Cancer Among Men with a Prostate-Specific Antigen Level < or = 4.0 ng per Milliliter,” New England Journal of Medicine 350 (2004): 2239–46.

398

G. L. Andriole et al. (PLCO Project Team), “Mortality Results from a Randomized Prostate-Cancer Screening Trial,” New England Journal of Medicine 360, 13 (2009): 1310–19.

399

F. H. Schröder et al. (ERSPC Investigators), “Screening and Prostate Cancer Mortality in a Randomized European Study,” New England Journal of Medicine 360, no. 13 (2009): 1320–28.

400

R. M. Martin et al. (CAP Trial Group), “Effect of a Low-Intensity PSA-based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial,” JAMA 319, no. 9 (2018): 883–95.

401

S. Loeb et al., “Complications After Prostate Biopsy: Data from SEER-Medicare,” Journal of Urology 186 (2011): 1830–34.

402

F. Fang et al., “Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United States,” Journal of the National Cancer Institute 102 (2010): 307–14.

403

J. J. Fenton et al., “Prostate-Specific Antigen—Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force,” JAMA 319(18): (2018): 1914–31.

404

https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening1?ds=1&s=psa.

405

H. S. Ahn, “Korea’s Thyroid Cancer ‘Epidemic’: Screening and Overdiagnosis,” New England Journal of Medicine 371 (2014): 1765–67.

406

H. R. Harach, K. O. Franssila, and V. M. Wasenius,” “Occult Papillary Carcinoma of the Thyroid: A “Normal” Finding in Finland—A Systematic Autopsy Study,” Cancer 56 (1985): 531–38.

407

P. T. Scardino, “Early Detection of Prostate Cancer,” Urologic Clinics of North America 16, no. 4 (November 1989): 635–55.

408

E. T. Thomas et al., “Prevalence of Incidental Breast Cancer and Precursor Lesions in Autopsy Studies: A Systematic Review and Meta-analysis,” BMC Cancer 17 (2017): 808.

409

J. M. P. Holly, “Cancer as an Endocrine Problem,” Clinical Endocrinology and Metabolism 22, no. 4 (2008): 539–50.

410

R. Doll and R. Peto, “The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today, Journal of the National Cancer Institute 1981;66(6):1191–1308

411

Islami et al., “Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States,” 31–54; D. M. Parkin, L. Boyd, and L. C. Walker, “The Fraction of Cancer Attributable to Lifestyle and Environmental Factors in the UK in 2010,” British Journal of Cancer 105, Suppl. 2 (2011): 77s–81s; M. C. Playdon et al., “Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis,” Journal of the National Cancer Institute 107, no. 12 (September 30, 2015): djv275, doi: 10.1093/jnci/djv275.

412

M. Arnold et al., “Global Burden of Cancer Attributable to High Body Mass Index in 2012: A Population-Based Study,” Lancet Oncology 16, no. 1 (2015): 36–46.

413

D. F. Williamson et al., “Prospective Study of Intentional Weight Loss and Mortality in Never-Smoking Overweight US White Women Aged 40–64 Years,” American Journal of Epidemiology 141 (1995): 1128–41.

414

N. V. Christou et al., “Bariatric Surgery Reduces Cancer Risk in Morbidly Obese Patients,” Surgery for Obesity and Related Disease 4 (2008): 691–95.

415

L. Sjostrom et al., “Effects of Bariatric Surgery on Cancer Incidence in Obese Patients in Sweden: Swedish Obese Subjects Study,” Lancet Oncology 10 (2009): 653–62.

416

T. D. Adams et al., “Cancer Incidence and Mortality After Gastric Bypass Surgery,” Obesity 17 (2009): 796–802.

417

H. Mackenzie et al., “Obesity Surgery and Risk of Cancer,” Mackenzie, H et al., British Journal of Surgery 105, no. 12 (November 2018): 1650–57; M. Derogar et al., “Increased Risk of Colorectal Cancer After Obesity Surgery,” Annals of Surgery 258 (2013): 983–88.

418

P. Kant and M. A. Hull, “Excess Body Weight and Obesity—The Link with Gastrointestinal and Hepatobiliary Cancer,” Nature Reviews Gastroenterology and Hepatology 8 (2011): 224–38.

419

C. Moreschi, “Beziehungen zwischen ernährung und tumorwachstum,” Z Immunitätsforsch, Orig. 2 (1909): 651–75.

420

V. D. Longo and L. Fontana, “Calorie Restriction and Cancer Prevention: Metabolic and Molecular Mechanisms,” Trends in Pharmacological Sciences 31, no. 2 (February 2010): 89–98.

421

M. Prisco et al., “Insulin and IGF-1 Receptors Signaling in Protection from Apoptosis,” Hormone and Metabolic Research 31 (1999): 80–89.

422

M. Kunkel et al., “Overexpression of GLUT-1 and Increased Glucose Metabolism in Tumors Are Associated with a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma,” Cancer 97 (2003): 1015–24; R. L. Derr et al., “Association Between Hyperglycemia and Survival in Patients with Newly Diagnosed Glioblastoma,” Journal of Clinical Oncology 27 (2009): 1082–86.

423

C. Yuan et al., “Influence of Dietary Insulin Scores on Survival in Colorectal Cancer Patients,” British Journal of Cancer 117, no. 7 (2017): 1079–87.

424

Vicente Morales-Oyarvide, “Dietary Insulin Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Finding from CALGB 89803,” Journal of the National Cancer Institute 111, no. 2 (2019): 1–10.

425

H. A. Krebs, “The Regulation of the Release of Ketone Bodies by the Liver,” Advances in Enzyme Regulation 4 (1966): 339–54.

426

W. D. DeWys, “Weight Loss and Nutritional Abnormalities in Cancer Patients: Incidence, Severity and Significance,” in K. C. Calman and K. C. H. Fearon, Clinics in Oncology (London: Saunders, 1986), 5:251–61.

427

M. J. Tisdale, “Biology of Cachexia,” Journal of the National Cancer Institute 89 (1997): 1763–73.

428

Минимальный расход энергии, необходимый для поддержания жизни: дыхания, работы внутренних органов.

429

C. R. Marinac et al., “Prolonged Nightly Fasting and Breast Cancer Risk: Findings from NHANES (2009–2010),” Cancer Epidemiology, Biomarkers, and Prevention 24, no. 5 (May 2015): 783–89.

430

C. R. Marinac et al., “Frequency and Circadian Timing of Eating May Influence Biomarkers of Inflammation and Insulin Resistance Associated with Breast Cancer Risk,” PLoS One 10, no. 8 (2015): e0136240, doi: 10.1371/journal.pone.0136240; Marinac et al., “Prolonged Nightly Fasting and Breast Cancer Risk,” 783–89.

431

S. J. Moschos, “The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications,” Oncology 63 (2002): 317–32.

432

Catherine R. Marinac et al., “Prolonged Nightly Fasting and Breast Cancer Prognosis,” JAMA Oncology 2, no. 8 (August 1, 2016): 1049–55, doi: 10.1001/jamaoncol.2016.0164.

433

F. M. Safdie et al., “Fasting and Cancer Treatment in Humans: A Case Series Report,” Aging 1, no. 12 (December 31, 2009): 988–1007; T. B. Dorff et al., “Safety and Feasibility of Fasting in Combination with Platinum-based Chemotherapy,” BMC Cancer 16, 360 (2016).

434

S. de Groot et al., “The Effects of Short-Term Fasting on Tolerance to (Neo) Adjuvant Chemotherapy in HER2-Negative Breast Cancer Patients: A Randomized Pilot Study,” BMC Cancer 15, 652 (2015).

435

C. Lee et al., “Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy,” Science Translational Medicine 4, no. 124 (March 7, 2012): 124ra27.

436

J. M. Evans et al., “Metformin and Reduced Risk of Cancer in Diabetic Patients,” BMJ 330 (2005): 1304–05; S. L. Bowker et al., “Increased Cancer-Related Mortality for Patients with Type 2 Diabetes Who Use Sulfonylureas or Insulin,” Diabetes Care 29 (2006): 254–58; G. Libby et al., “New Users of Metformin Are at Low Risk of Incident Cancer: A Cohort Study Among People with Type 2 Diabetes,” Diabetes Care 32 (2009): 1620–25; D. Li et al., “Antidiabetic Therapies Affect Risk of Pancreatic Cancer,” Gastroenterology 137 (2009): 482–88; G. W. Landman et al., “Metformin Associated with Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16, Diabetes Care 33 (2010): 322–26.

437

M. Bodmer et al., “Long-Term Metformin Use Is Associated with Decreased Risk of Breast Cancer,” Diabetes Care 33 (2010): 1304–08.

438

P. J. Goodwin et al., “Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer,” Clinical Breast Cancer 8 (2008): 501–5.

439

S. Yoshizawa et al., “Antitumor Promoting Activity of (-)-epigallocatechin Gallate, the Main Constituent of ‘Tannin’ in Green Tea,” Phytotherapy Research 1 (1987): 44–47.

440

I. J. Chen et al., “Therapeutic Effect of High-Dose Green Tea Extract on Weight Reduction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial,” Clinical Nutrition 35, no. 3 (June 2016): 592–99, doi: 10.1016/j.clnu.2015.05.003; A. G. Dulloo et al., “Efficacy of a Green Tea Extract Rich in Catechin Polyphenols and Caffeine in Increasing 24-h Energy Expenditure and Fat Oxidation in Humans,” American Journal of Clinical Nutrition 70, no. 6 (December 1999): 1040–45; S. Rudelle et al., “Effect of a Thermogenic Beverage on 24-Hour Energy Metabolism in Humans,” Obesity 15 (2007): 349–55.

441

T. Nagao et al., “A Catechin-Rich Beverage Improves Obesity and Blood Glucose Control in Patients with Type 2 Diabetes,” Obesity 17, no. 2 (February 2009): 310–17, doi: 10.1038/oby.2008.505.

442

P. Bogdanski et al., “Green Tea Extract Reduces Blood Pressure, Inflammatory Biomarkers, and Oxidative Stress and Improves Parameters Associated with Insulin Resistance in Obese, Hypertensive Patients,” Nutrition Research 32(6 (June 2012): 421–27, doi: 10.1016/j.nutres.2012.05.007.

443

H. Iso et al., “The Relationship Between Green Tea and Total Caffeine Intake and Risk for Self-Reported Type 2 Diabetes Among Japanese Adults,” Annals of Internal Medicine 144, no. 8 (April 18, 2006): 554–62.

444

K. Nakachi et al., “Preventive Effects of Drinking Green Tea on Cancer and Cardiovascular Disease: Epidemiological Evidence for Multiple Targeting Prevention,” Biofactors 13, nos. 1–4 (2000): 49–54.

445

H. Fujiki et al., “Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: From Early Investigations to Current Focus on Human Cancer Stem Cells,” Molecules and Cells 41, no. 2 (2018): 73–82.

446

M. Shimizu al., “Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study,” Cancer Epidemiology, Biomarkers, and Prevention 17 (2008): 3020–25.

447

S. Bettuzzi et al., “Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study,” Cancer Research 66 (2006): 1234–40.

448

S. A. Hoption Cann, J. P. van Netten, and C. van Netten, “Acute Infections as a Means of Cancer Prevention: Opposing Effects to Chronic Infections? Cancer Detection and Prevention 30 (2006): 83–93.

449

S. J. Oiseth et al., “Cancer Immunotherapy: A Brief Review of the History, Possibilities, and Challenges Ahead,” Journal of Cancer Metastasis and Treatment 3 (2017): 250–61.

450

P. Kucerova and M. Cervinkova, “Spontaneous Regression of Tumour and the Role of Microbial Infection: Possibilities for Cancer Treatment,” Anti-Cancer Drugs 27 (2016): 269–77.

451

Hoption Cann, van Netten, and van Netten, “Acute Infections as a Means of Cancer Prevention,” 83–93.

452

https://www.newyorker.com/magazine/2012/04/23/the-t-cell-army. 6. W. B. Coley, “The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas: With a Report of Ten Original Cases,” American Journal of the Medical Sciences 105, no. 5 (May 1893): 3–11.

453

W. B. Coley, “The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas: With a Report of Ten Original Cases,” American Journal of the Medical Sciences 105, no. 5 (May 1893): 3–11.

454

P. Ehrlich, “Uber den jetzigen Stand der Karzinomforschung,” Ned Tijdschr Geneeskd 5 (1909): 273–90.

455

F. M. Burnet, “The Concept of Immunological Surveillance,” Progress in Experimental Tumor Research 13 (1970): 1–27.

456

D. Ribatti, “The Concept of Immune Surveillance Against Tumors: The First Theories,” Oncotarget 8, no. 4 (2017): 7175–80.

457

L. A. Loeb, “Human Cancers Express Mutator Phenotypes: Origin, Consequences and Targeting,” Nature Reviews Cancer 11 (2011): 450–57.

458

N. S. Bajaj et al., “Donor Transmission of Malignant Melanoma in a Lung Transplant Recipient 32 Years After Curative Resection,” Transplant Immunology 23, no. 7 (2010): e26–e31, doi: 10.1111/j.1432–2277.2010.01090.x.

459

R. Pearl, “Cancer and tuberculosis” American Journal of Hygiene 9 (1929): 97–159.

460

A. Morales, D. Eidinger, and A. W. Bruce, “Intercavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors,” Journal of Urology 116, no. 2 (August 1976): 180–83.

461

A. Morales, “Treatment of Carcinoma In Situ of the Bladder with BCG: A Phase II Trial,” Cancer Immunology, Immunotherapy 9, nos. 1–2 (1980): 69–72.

462

G. Redelman-Sidi, M. S. Glickman, and B. H. Bochner, “The Mechanism of Action of BCG Therapy for Bladder Cancer: A Current Perspective,” Nature Reviews Urology 11, no. 3 (March 2014): 153–62.

463

Heidi Ledford, “The Killer Within,” Nature 508 (2014): 24–26.

464

https://www.wired.com/story/meet-jim-allison-the-texan-who-just-won-a-nobel-cancer-breakthrough/.

465

D. R. Leach, M. F. Krummel, and J. P. Allison, “Enhancement of Antitumor Immunity by CTLA-4 Blockade,” Science 271 (1996): 1734–36.

466

Чарльз Гребер, «Открытие. Новейшие достижения в иммунотерапии для борьбы с новообразованиями», изд. «Бомбора», 2020 г.

467

D. Schadendorf et al., “Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology 33 (2015): 1889–94.

468

https://www.nobelprize.org/uploads/2018/10/press-medicine2018.pdf.

469

J. D. Wolchok et al., “Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 377 (2017): 1345–56, doi: 10.1056/NEJMoa1709684.

470

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-first-fda-approval-car-t-cell-immunotherapy.

471

M. A. Postow et al., “Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma,” New England Journal of Medicine 366 (2012): 925–31.

472

R. H. Mole, “Whole Body Irradiation: Radiobiology or Medicine?” British Journal of Radiology 26, no. 305 (May 1953): 234–41.

473

G. Ehlers et al., “Abscopal Effect of Radiation in Papillary Adenocarcinoma,” British Journal of Radiology 46 (1973): 222–24.

474

N. Dagoglu et al., “Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases,” Cureus 11, no. 2 (February 2019): e4103.

475

E. B. Golden et al., “Local Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor to Generate Abscopal Responses in Patients with Metastatic Solid Tumours: A Proof-of-Principle Trial,” Lancet Oncology 16 (2015): 795–803.

476

M. T. Yilmaz et al., “Abscopal Effect, from Myth to Reality: From Radiation Oncologists’ Perspective,” Cureus 11, no. 1 (January 2019): e3860, doi: 10.7759/cureus.3860.

477

C. Vanpouille-Box et al., “DNA Exonuclease Trex1 Regulates Radiotherapyinduced Tumour Immunogenicity,” Nature Communications 8 (June 9, 2017): 915618, doi: 10.1038/ncomms15618.

478

W. S. M. E. Theelen et al., “Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial,” JAMA Oncology 5, no. 9 (July 11, 2019): 1276–1282: doi: 10.1001/jamaoncol.2019.1478.

479

R. A. Gatenby, “Population Ecology Issues in Tumor Growth,” Cancer Research 51, no. 10 (May 15, 1991): 2542–47.

480

https://www.wired.com/story/cancer-treatment-darwin-evolution/.

481

J. Zhang et al., “Integrating Evolutionary Dynamics into Treatment of Metastatic Castrate-Resistant Prostate Cancer,” Nature Communications 8, no. 1 (November 28, 2017): 1816, doi: 10.1038/s41467-017-01968–5.

482

Слэм-данк – в баскетболе зрелищный бросок мяча сверху сквозь кольцо в прыжке. – Прим. пер.

483

T. Fojo et al., “Unintended Consequences of Expensive Cancer Therapeutics: The Pursuit of Marginal Indications and a Me-Too Mentality that Stifles Innovation and Creativity,” JAMA Otolaryngology—Head and Neck Surgery 140, no. 12 (2014): 1225–36.